Diffuse large B-cell lymphoma: open trials in United States

131 open trials have a site in United States. Registry data; only the trial team decides who can take part.

NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL
Trial Treatment · Phase 1 · Verismo Therapeutics
Winship Cancer Institute of Emory University, Atlanta · Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver · The University of Kansas Cancer Center, Fairway · Rutgers Cancer Institute, New Brunswick · Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Registry updated 2026-04-14
NCT05544968
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Trial Treatment · Phase 1 · Medical College of Wisconsin
Froedtert & the Medical College of Wisconsin, Milwaukee
Registry updated 2026-04-03
NCT06451497
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Trial Treatment · Phase 1 · Zumutor Biologics Inc.
NEXT Oncology, Austin, TX 78758 · Dana-Farber Cancer Institute, Boston · NEXT Oncology, San Antonio
Registry updated 2026-04-02
NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Trial Treatment · Phase 1 · Nurix Therapeutics, Inc.
National Institutes of Health Clinical Center, Bethesda · The University of Chicago Medical Center, Chicago · University of Cincinnati Medical Center, Cincinnati · OSU Wexner Medical Center, Columbus · Baylor University Medical Center, Dallas · Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver · City of Hope, Duarte · MD Anderson Cancer Center, Houston · Mount Sinai Comprehensive Cancer Center, Miami Beach · Tennessee Oncology, Nashville · Memorial Sloan-Kettering Cancer Center, New York · University of California Irvine, Orange · Huntsman Cancer Institute/University of Utah, Salt Lake City · University of California San Francisco Medical Center, San Francisco · Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota · Swedish Cancer Institute, Seattle
Registry updated 2026-03-20
NCT05256641
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Trial Treatment · Phase 1/2 · Jonsson Comprehensive Cancer Center
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles · University of Oklahoma, Oklahoma City · University of California Davis Comprehensive Cancer Center, Sacramento
Registry updated 2026-03-10
NCT05800366
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Trial Treatment · Phase 2 · Jennifer Crombie, MD
Beth Israel Deaconess Medical Center, Boston · Dana-Farber Cancer Institute, Boston · University of Miami - Sylvester Cancer Center, Miami
Registry updated 2026-03-05
NCT05934448
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Trial Treatment · Phase 2 · Jennifer Crombie, MD
Dana-Farber Cancer Institute, Boston · Memorial Sloan-Kettering Cancer Center, New York
Registry updated 2026-03-05
NCT07042438
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Trial Treatment · Phase 2 · City of Hope Medical Center
City of Hope Medical Center, Duarte
Registry updated 2026-03-05
NCT05873712
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Trial Treatment · Phase 2 · Aseel Alsouqi
Ohio State University Comprehensive Cancer Center, Columbus · Icahn School of Medicine at Mount Sinai, New York · Huntsman Cancer Institute, Salt Lake City
Registry updated 2026-03-03
NCT05755087
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Trial Treatment · Phase 1 · Lapo Alinari
Ohio State University Comprehensive Cancer Center, Columbus
Registry updated 2026-02-27
NCT06209619
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Trial Treatment · Phase 1 · Nathan Denlinger
Ohio State University Comprehensive Cancer Center, Columbus
Registry updated 2026-02-27
NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Trial Treatment · Phase 1/2 · Medical College of Wisconsin
Medical College of Wisconsin and Froedtert Hospital, Milwaukee
Registry updated 2026-02-23
NCT05432635
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Trial Treatment · Phase 1 · City of Hope Medical Center
City of Hope Medical Center, Duarte
Registry updated 2026-02-23
NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Trial Treatment · Phase 1 · Newave Pharmaceutical Inc
University of Cincinnati, Cincinnati · Ohio State University, Columbus · Duke Univerisity, Durham · Huntsman Cancer Institute/University of Utah, Salt Lake City
Registry updated 2026-02-13
NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms
Trial Treatment · Phase 1 · Schrödinger, Inc.
Beth Israel Deaconess Medical Center, Boston · Roswell Park Comprehensive Cancer Center, Buffalo · Gabrail Cancer & Research Center, Canton · The Ohio State University - The James Cancer Hospital, Columbus · University of Texas, Southwestern, Dallas · Duke University, Durham · Banner Health- MD Anderson Cancer Center, Gilbert · Regional Cancer Care Associates, Hackensack · Medical College of Wisconsin, Milwaukee · Christiana Care Hospital - Helen F Graham Cancer Center, Newark · Weill Cornell, New York · Napa Research, Pompano Beach · Oregon Health and Science University Knight Cancer Institute, Portland · Rhode Island Hospital, Providence · Fred Hutchinson Cancer Center, Seattle · Montefiore Medical Center, The Bronx
Registry updated 2026-02-13
NCT06191887
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Trial Treatment · Phase 1 · Mayo Clinic
Mayo Clinic in Florida, Jacksonville
Registry updated 2026-02-13
NCT05800405
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Trial Treatment · Early phase 1 · City of Hope Medical Center
City of Hope Medical Center, Duarte
Registry updated 2026-02-04
NCT06693830
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Trial Treatment · Hua-Jay J Cherng, MD
Columbia University, New York
Registry updated 2026-01-23
NCT06846463
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Trial Treatment · Phase 2 · Virginia Commonwealth University
Virginia Commonwealth University, Richmond
Registry updated 2026-01-23
NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Trial Treatment · Phase 1 · OncoNano Medicine, Inc.
Gabrail Cancer Center Research, Canton · Ohio State University, Columbus · University of Texas Southwestern Medical Center, Dallas · Virginia Cancer Specialists PC, Fairfax · MD Anderson Cancer Center, Houston · California Research Institute, Los Angeles · Allegheny Health Network, Pittsburgh · UPMC Hillman Cancer Center, Pittsburgh · BRCR Global, Tamarac
Registry updated 2025-12-24
NCT06736613
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Trial Treatment · Phase 2 · Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge · Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack · Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison · Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown · Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale · Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York · Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre
Registry updated 2025-12-18
NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Research · Medical College of Wisconsin
Froedtert Hospital/Medical College of Wisconsin, Milwaukee
Registry updated 2025-11-10
NCT06828991
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Trial Treatment · Phase 2 · Danielle Wallace
Wilmot Cancer Institute, Rochester
Registry updated 2025-10-20
NCT05780034
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Trial Treatment · Phase 1 · Accutar Biotechnology Inc
University of North Carolina, Chapel Hill · University Hospitals Cleveland Medical Center*, Cleveland · The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus · University of Texas Southwestern Medical Center, Dallas · Colorado Blood Cancer Institute, Denver · Tennessee Oncology, Nashville · Oregon Health Science University, Portland · Florida Cancer Specialists, Sarasota · Swedish Cancer Institute, Seattle
Registry updated 2025-10-02
NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
Trial Treatment · Phase 1 · Nurix Therapeutics, Inc.
University of Colorado School of Medicine, Aurora · University of North Carolina, Chapel Hill · University of Virginia, Charlottesville · University of Chicago, Chicago · City of Hope, Duarte · MD Anderson Cancer Center, Houston · University of Southern California, Los Angeles · University of Oklahoma, Oklahoma City · University of California San Francisco, San Francisco · Fred Hutchinson Cancer Center, Seattle
Registry updated 2025-09-09

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error